STAT3 and breast carcinoma: Yang et al. reported that TAMs secrete IL-10 which upregulates B-cell lymphoma 2 (BCL-2) and STAT3 expressions and as a result activates the IL-10-STAT3-BCL2 pathway in breast cancer cells, which increases drug resistance [67].